Applying the AIM Concept in Support of Developing Improved In Vitro–In Vivo Relationships for OIPs - Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products - page 380

a NGI at 30 L/min

100

USP Throat

Alberta Throat

80

60

40

20

0

1
Aerodynamic Diameter (

10

μ m)

pMDI-delivered salbutamol sulfate

b

NGI at 60 L/min

100

USP Throat

Alberta Throat

80

60

40

20

0

1
Aerodynamic Diameter (

10

μ m)

DPI-delivered salbutamol sulfate

Fig. 12.13 Comparative APSDs of MDI-delivered salbutamol for an NGI equipped with either
Ph.Eur./USP induction port or AIT and operated with Q at 30 L/min ( From [ 45 ] —used with
permission )